Efficacy 0f Repatha across high-risk patient populations reinforced at ACC.21

Amgen announced the presentation of four cardiovascular research abstracts, including final data from the Repatha (evolocumab) open label extension trial of patients living with HIV who have high cholesterol as well as new data from FOURIER evaluating biomarkers of major cardiovascular (CV) events, including complex revascularization procedures. Additional abstracts to be presented include a simulation comparing the impact of different LDL-C guidelines on CV risk reduction, as well as negative control outcomes to assess residual bias when comparing PCSK9 inhibitors to other treatments. These analyses will be presented at the American College of Cardiology's 70th Annual Scientific Session & Expo (ACC.21), May 15-17, 2021. The data in HIV confirm the safety and efficacy of Repatha across different patient populations and contribute to Amgen's PROFICIO (Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different POpulations) program of clinical and real-world evidence studies investigating the impact of Repatha on cardiovascular disease. To date, the PROFICIO program consists of 50 clinical trials including more than 47,000 patients worldwide with eight real-world evidence studies1. These studies provide the body of evidence for treatment in a variety of high-risk patients and have contributed to Repatha being approved in more than 75 countries. Notably, Amgen recently passed the milestone of more than one million patients receiving Repatha worldwide .